IgG4-Related Disease is the Primary Mimic to Consider
The disease most likely to mimic giant cell arteritis with retroperitoneal fibrosis and systemic fibrotic changes is IgG4-related disease (IgG4-RD). This condition can present with both large vessel vasculitis (mimicking GCA) and retroperitoneal fibrosis, creating a clinical picture nearly identical to what you're describing.
Why IgG4-Related Disease is the Key Differential
IgG4-RD accounts for approximately 40% of inflammatory abdominal aortic aneurysm/periaortitis cases and a significant portion of retroperitoneal fibrosis cases 1. More importantly, 57% of "idiopathic" retroperitoneal fibrosis cases are actually IgG4-related 2, making this the single most common underlying cause of what appears to be idiopathic RPF.
Critical Distinguishing Features
The histopathologic triad that separates IgG4-related RPF from other causes includes:
- Storiform fibrosis (p = 0.006 for diagnostic significance) 2
- Lymphoplasmacytic infiltrate (p = 0.006) 2
- Tissue eosinophilia (p = 0.0002) 2
The most useful diagnostic criterion is an IgG4/total IgG ratio >40% in tissue biopsies, which is more reliable than absolute IgG4+ plasma cell counts, especially in highly fibrotic lesions 2.
Other Important Mimics to Exclude
Granulomatosis with Polyangiitis (GPA)
GPA can present with retroperitoneal fibrosis in the peri-iliac region, though this is rare 3. Look for:
- Cavitating pulmonary lesions
- Elevated ANCA (particularly PR3-ANCA)
- Necrotizing granulomas on biopsy
- Sinonasal or renal involvement
Malignancy-Associated RPF
Cancer has a standardized incidence ratio of 2.2 in RPF patients, rising to 9.9 within the first year of RPF diagnosis 4. Renal pelvis cancer and multiple myeloma show particularly strong associations 4. This is critical because:
- Cancers diagnosed within 1 year of RPF have more advanced stages
- Mortality is significantly higher in this group
- Always obtain tissue diagnosis to exclude malignancy
True Giant Cell Arteritis with RPF
While rare, GCA itself can occasionally present with retroperitoneal fibrosis 5. However, this represents actual GCA rather than a mimic—the key is determining whether the aortitis is GCA or IgG4-related aortitis.
Diagnostic Algorithm
Obtain tissue biopsy of the retroperitoneal mass (essential, not optional)
- Assess IgG4/IgG ratio (>40% suggests IgG4-RD)
- Look for storiform fibrosis, obliterative phlebitis, eosinophilia
- Rule out malignancy and necrotizing granulomas
Measure serum IgG4 levels (supportive but not diagnostic alone)
Screen for multi-organ IgG4-RD involvement:
- Pancreas (autoimmune pancreatitis)
- Salivary/lacrimal glands
- Biliary tree (sclerosing cholangitis)
- Lungs, kidneys, lymph nodes
Check ANCA titers to exclude GPA
Evaluate for malignancy with age-appropriate cancer screening, particularly within the first year of RPF diagnosis
Treatment Implications
This distinction matters enormously for treatment:
- IgG4-RD responds to glucocorticoids as first-line therapy, with rituximab as steroid-sparing alternative 1, 6
- GCA requires urgent high-dose glucocorticoids to prevent ischemic complications 7, with tocilizumab as the only approved biologic 8
- GPA requires cyclophosphamide or rituximab with glucocorticoids 3
Critical Pitfall to Avoid
Do not assume all aortitis with RPF is GCA simply because the patient is elderly. The demographics overlap significantly (mean age ~58-60 years, male predominance in both conditions) 2. Without tissue diagnosis showing the characteristic IgG4+ plasma cell infiltration pattern, you risk treating IgG4-RD as GCA or vice versa, with potentially serious consequences including treatment failure or unnecessary toxicity.
The presence of extra-retroperitoneal manifestations typical of IgG4-RD (pancreatic, salivary gland, or biliary involvement) strongly favors IgG4-related disease over GCA 2.